Microbix's flu vaccine-yield booster to be independently evaluated

By Angela McDaniels

Seattle, Dec. 6 - Microbix Biosystems Inc. said an independent influenza research laboratory will evaluate the ability of the company's biological technology to boost influenza vaccine production output.

Microbix is transferring its technology to the laboratory, located in a North American teaching hospital, where the effectiveness of the process will be tested and assessed. The final report is expected in about six months, the company said.

"Numerous studies have already shown significant gains in viral yield. We look forward to this additional assessment as it will provide independent, objective guidance to the manufacturers of influenza vaccines," said William J. Gastle, president and chief executive officer, in a company news release.

Annual global vaccine production capacity is currently only 300 million doses, far short of the potential pandemic requirement, the company said.

Microbix is based in Toronto, where it develops biological technologies and commercializes them through global partners. Its products include biotherapeutic drugs, vaccines and infectious disease diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.